Why the study?
Does anti-Xa activity measured by different assays correlate and predict VTE or massive bleeding in major orthopedic surgery patients receiving edoxaban?
Does anti-Xa activity measured by different assays correlate and predict VTE or massive bleeding in major orthopedic surgery patients receiving edoxaban?
Anti-Xa levels measured by specific assays may predict VTE risk but not massive bleeding risk in orthopedic surgery patients on edoxaban.
Answers are grounded in this paper and cite their sources.
Anti-Xa activity rises progressively with edoxaban after orthopedic surgery; hypothesis-generating for accumulation effects and requires prospective validation.
BACKGROUND: Measurement of edoxaban plasma concentration has been gathering attention in major orthopedic surgery patients receiving edoxaban for the prevention of venous thromboembolism (VTE). METHODS: The anti-Xa activity was measured one hour after edoxaban intake using 3 different assays in 200 patients after major orthopedic surgery. RESULTS: The anti-Xa activities on Day 8 were significantly higher than those on Day 4 and those on Day 4 were significantly higher than those on Day 1. The anti-Xa activities in two assays closely correlated with each other, but the other anti-Xa assay did not correlated with other two assays. The anti-Xa activities as detected in the three Xa assays were significantly higher in the patients without deep vein thrombosis (DVT) than in those with DVT on Day 4. Additionally, there were no significant differences in the anti-Xa activities of assays A, B and C between patients with and without massive bleeding (MB) on Days 1, 4, 8 and 15. CONCLUSION: The results of this study suggest that anti-Xa level could be predictive of the risk of VTE, but not of the risk of massive bleeding.
No takes yet. Share an insight, caveat, or question.
Ikejiri et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: